EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial

Ying Wang iD, Caroline Ivanne Le Roy iD, Jing Li iD, Shuping Han iD, Zhiwei Liu iD, Anirban Lahiry iD, Himanshu Sahu iD, Qiaoji Li iD, Jie Dong iD, Alric Mondragon iD, Tinu Mary Samuel iD, Wei Cai iD

JMIR Research Protocols · 2025

DOI: 10.2196/66489 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Ying Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Infant Formula, Trisaccharides, Oligosaccharides. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bioactive compounds, such as human milk oligosaccharides (HMOs), impact the development of the intestinal microbiome and immune maturation in early life. They have been shown to result in positive benefits, including improved gut health, reduced frequency of infections, and age-appropriate growth when added to infant formula. However, data supporting the added value of including these HMOs in early-stage infant formula is currently lacking among Chinese infants.

Objective

In this double-blind randomized controlled trial including a nonrandomized reference breastfed group, we will test the efficacy of ready-to-feed infant formula containing 2 HMOs (2-fucosyllactose and lacto-N-neotetraose) on Bifidobacteria abundance, gut microbiome, gut and immune health, growth, and quality of life.

Methods

Healthy infants will be enrolled between 3 and 14 days after birth at 5 sites in China and randomized to either the experimental group (fed ready-to-feed infant formula containing 2 HMOs) or the control group (fed the same ready-to-feed infant formula without the 2 HMOs), using a dynamic allocation algorithm with double blinding. Infants will receive trial formula until age 6 months and will be followed up until age 12 months. The breastfed group will serve as a reference. The primary end point will be Bifidobacteria abundance in fecal samples at 3 months, measured via quantitative polymerase chain reaction. Secondary end points will include fecal microbiome (including taxonomy, diversity, functionality, and metabolites), fecal markers of immune health, gastrointestinal tolerance, stooling patterns, immune competence (overall state of the immune system), sleep quality, growth, quality of life, medication use, and physician-reported adverse events. A 2-sided test at the 5% significance level will be used for statistical testing.

Results

The study received ethical approval in March 2024 and will be completed by the end of 2026, which will be followed by a publication in a peer-reviewed journal.

Conclusions

The Starter Liquid Infant Formula Trial (STARLIT) will be one of the first to assess the efficacy of these 2 HMOs among Chinese infants on gut and immune health, in addition to clinically relevant outcomes such as quality of life, growth, and adverse events. This study should help to demonstrate that an increase in the growth of beneficial Bifidobacteria in response to intake of 2-fucosyllactose and lacto-N-neotetraose may have a broader impact on overall gut microbiome composition and infant gut and immune health. Trial Registration ClinicalTrials.gov NCT06361719; https://clinicaltrials.gov/study/NCT06361719 International Registered Report Identifier (IRRID) PRR1-10.2196/66489

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Infant FormulaTrisaccharidesOligosaccharidesHumansDouble-Blind MethodInfantGastrointestinal MicrobiomeChinaInfant, NewbornFemaleMaleMilk, HumanBifidobacteriumRandomized Controlled Trials as TopicQuality of LifeFecesBreast FeedingEast Asian People

Stichwörter der Autor:innen

Bifidobacteriagastrointestinal tolerancegrowthgut microbiomehuman milk oligosaccharidesimmune healthinfant nutrition

Substanzen

2'-fucosyllactoseTrisaccharidesOligosaccharideslacto-N-neotetraose

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Clinical Research Unit, Société des Produits Nestlé SA, 1000 Lausanne, Switzerland.
  • Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, China.
  • The International Peace Maternity and Child Health Hospital of China Welfare Institute, Shanghai, China.
  • Clinical Research Unit, Nestlé Research, Beijing, China.

ORCID-Profile: Ying Wang, Caroline Ivanne Le Roy, Jing Li, Shuping Han, Zhiwei Liu, Anirban Lahiry, Himanshu Sahu, Qiaoji Li, Jie Dong, Alric Mondragon, Tinu Mary Samuel, Wei Cai

Zitieren

APA

Wang, Y., Le Roy, C. I., Li, J., Han, S., Liu, Z., Lahiry, A., Sahu, H., Li, Q., Dong, J., Mondragon, A., Samuel, T. M., & Cai, W. (2025). Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/66489

Vancouver

Wang Y, Le Roy CI, Li J, Han S, Liu Z, Lahiry A, et al. Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/66489

BibTeX
@article{Wang2025,
  author = {Wang, Ying and Le Roy, Caroline Ivanne and Li, Jing and Han, Shuping and Liu, Zhiwei and Lahiry, Anirban and Sahu, Himanshu and Li, Qiaoji and Dong, Jie and Mondragon, Alric and Samuel, Tinu Mary and Cai, Wei},
  title = {Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/66489}
}
Kostenlos starten →